#	Pagina
attuale pagina	/open-h2020/projects/226546/index.html

Opendata, web and dolomites

VANGUARD SIGNED

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

VANGUARD project word cloud

Explore the words cloud of the VANGUARD project. It provides you a very rough idea of what is the project "VANGUARD" about.

limited pd therapy edited utilizing cd47 molecules urgent beta destruction scientists replacement therapeutic worldwide matrix assembling overexpress anti diabetes epithelial larger xenogeneic safety haec revascularization immunomodulatory producing social implantation haecs constructs genome extracellular immune accessibility blood completion rapid vanguard academic vivo implantability disease locally infinite confer human clinical atmp reconstituted protection l1 patients majority ethical insulin medicinal translational vast delivered organoids suffer potency components stem pancreas construct endothelial chronic graft managed langerhans hydrogel vitro amniotic biocompatibility transplantation smes mice expertise forty inflammatory boecs release therapies cells model outgrowth complications diabetic membrane mechanical individuals cell consists ngo million bioartificial hla devastating sources islet

Project "VANGUARD" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITE DE GENEVE Organization address address: RUE DU GENERAL DUFOUR 24 city: GENEVE postcode: 1211 website: www.unige.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Switzerland [CH]
Total cost	6˙844˙625 €
EC max contribution	6˙844˙625 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2019-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2020
Duration (year-month-day)	from 2020-01-01 to 2024-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITE DE GENEVE UNIVERSITE DE GENEVE Organization address address: RUE DU GENERAL DUFOUR 24 city: GENEVE postcode: 1211 website: www.unige.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (GENEVE)	coordinator	1˙995˙946.00
2	OSPEDALE SAN RAFFAELE SRL OSPEDALE SAN RAFFAELE SRL Organization address address: VIA OLGETTINA 60 city: MILANO postcode: 20132 website: www.hsr.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	participant	1˙049˙500.00
3	UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO Organization address address: DUOMO 6 city: VERCELLI postcode: 13100 website: www.unipmn.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (VERCELLI)	participant	936˙875.00
4	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 website: www.uni-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	804˙375.00
5	KUGELMEIERS AG KUGELMEIERS AG Organization address address: BAHNHOFSTRASSE 40 city: ERLENBACH postcode: 8703 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (ERLENBACH)	participant	701˙250.00
6	UNIVERSITE LYON 1 CLAUDE BERNARD UNIVERSITE LYON 1 CLAUDE BERNARD Organization address address: BOULEVARD DU 11 NOVEMBRE 1918 NUM43 city: VILLEURBANNE CEDEX postcode: 69622 website: www.univ-Iyon1.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (VILLEURBANNE CEDEX)	participant	523˙812.00
7	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Organization address address: DR MOLEWATERPLEIN 40 city: ROTTERDAM postcode: 3015 GD website: www.erasmusmc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (ROTTERDAM)	participant	393˙116.00
8	ACCELOPMENT AG ACCELOPMENT AG Organization address address: SEEFELDSTRASSE 198 city: ZUERICH postcode: 8008 website: www.accelopment.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (ZUERICH)	participant	384˙750.00
9	EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION Organization address address: WESTERDOKSDIJK 423 city: AMSTERDAM postcode: 1013 BX website: www.esot.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	55˙000.00

Map

Project objective

Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies (pancreas or islet of Langerhans transplantation). There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients. The VANGUARD project aims to deliver an Advanced Therapeutic Medicinal Product (ATMP) of high translational potential, with properties of increased functionality and implantability and protection from immune destruction. We will construct a bioartificial pancreas by assembling insulin- producing organoids, composed of islet cells, human amniotic epithelial cells (hAEC) and blood outgrowth endothelial cells (BOECs), into an amniotic membrane-derived hydrogel. Components of the amniotic membrane will provide extracellular matrix and mechanical protection and confer their well-defined anti-inflammatory and immunomodulatory properties to the constructs. hAECs will be genome-edited to overexpress and locally release immunomodulatory molecules (HLA-G, HLA-E, CD47 and PD-L1) and endothelial cells will enhance graft revascularization. Functionality, biocompatibility, potency and safety of the bioartificial pancreas will be assessed in vitro and in vivo by implantation in mice reconstituted with a human immune system as pre-clinical model. The consortium consists of 5 academic institutions with leading scientists in their field, 2 SMEs and 1 NGO with expertise in ethical and social aspects of transplantation. The ATMP delivered upon completion of the project will provide a model for rapid development of a bioartificial pancreas, utilizing “infinite” sources of insulin-producing cells (stem cell-derived, xenogeneic), and available to all type 1 diabetic patients before they develop the devastating chronic complications of the disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VANGUARD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VANGUARD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More